March 26, 2018 / 6:30 AM / 7 months ago

BRIEF-Verona Pharma Says Positive Top-Line Data From Phase 2B Trial Of RPl554

March 26 (Reuters) - Verona Pharma Plc:

* VERONA PHARMA REPORTS POSITIVE TOP-LINE DATA FROM PHASE 2B CLINICAL TRIAL OF RPL554 FOR MAINTENANCE TREATMENT OF COPD

* PRIMARY ENDPOINT MET; RPL554 PRODUCED CLINICALLY AND STATISTICALLY SIGNIFICANT IMPROVEMENTS IN LUNG FUNCTION AT ALL DOSES

* VERONA PHARMA - CLINICALLY RELEVANT SECONDARY ENDPOINTS WERE ALSO MET, INCLUDING STATISTICALLY SIGNIFICANT, PROGRESSIVE IMPROVEMENTS IN COPD SYMPTOMS

* RPL554 WAS WELL TOLERATED AT ALL DOSE LEVELS IN THIS FOUR WEEK 400 PATIENT STUDY Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below